



# New Hampshire Medicaid Fee-for-Service (FFS) Program

## Prior Authorization/Non-Preferred Drug Approval Form

Skin Disorders

DATE OF MEDICATION REQUEST:    /    /

### SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

FIRST NAME:

MEDICAID ID NUMBER:

DATE OF BIRTH:

GENDER:  Male  Female

Drug Name

Strength

Dosing Directions

Length of Therapy

### SECTION II: PRESCRIBER INFORMATION

LAST NAME:

FIRST NAME:

SPECIALTY:

NPI NUMBER:

PHONE NUMBER:

FAX NUMBER:

### SECTION III: CLINICAL HISTORY

**Atopic Dermatitis– Other indications skip to *question 8*.**

1. What is the patient's diagnosis or condition that this medication is being prescribed to treat?

\_\_\_\_\_

2. What is the patient's age?

\_\_\_\_\_

3. Is a dermatologist, immunologist, or allergist prescribing this medication, **or** has one been consulted in this case?     Yes     No

4. Has there been a failure, contraindication, or intolerance to topical corticosteroid therapy?     Yes     No

If **yes**, describe treatment failure, contraindication, or intolerance and provide date:

\_\_\_\_\_



**New Hampshire Medicaid Fee-for-Service (FFS) Program**  
**Prior Authorization/Non-Preferred Drug Approval Form**  
 Skin Disorders

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

5. Has the patient been treated with a topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus) in the past?  Yes  No

If **yes**, provide drug name and duration of therapy:

6. **Opzelura® and Zoryve® only:** Has the patient been treated with a topical phosphodiesterase-4 inhibitor (e.g., crisaborole) in the past?  Yes  No

If **yes**, provide drug name and duration of therapy:

7. **Systemic treatment only:** Will the patient also receive therapy with any other monoclonal antibody biologic (e.g., tezepelumab, omalizumab, mepolizumab, reslizumab, dupilumab)?  Yes  No

**Other Indications (8-11)**

8. Does the patient have a diagnosis of nonsegmental vitiligo?  Yes  No

9. What is the patient's age? \_\_\_\_\_

10. Is the prescriber a dermatologist?  Yes  No

11. Provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.



**New Hampshire Medicaid Fee-for-Service (FFS) Program**  
**Prior Authorization/Non-Preferred Drug Approval Form**  
 Skin Disorders

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION IV: NON-PREFERRED DRUG APPROVAL CRITERIA**

*Chapter 188 of the Laws of 2004 requires that Medicaid only cover non-preferred drugs upon a finding of medical necessity by the prescribing physician. Chapter 188 requires that you base your determination of medical necessity on the following criteria.*

Allergic reaction. **Describe reaction:**

Drug-to-drug interaction. **Describe reaction:**

Previous episode of an unacceptable side effect or therapeutic failure. **Provide clinical information:**

Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to a preferred drug. **Provide clinical information:**

Age-specific indications. **Provide patient age and explain:**

Unique clinical indication supported by FDA approval or peer-reviewed literature. **Explain and provide a reference:**

Unacceptable clinical risk associated with therapeutic change. **Please explain:**

**I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.**

**PRESCRIBER'S SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_